Medical Device Contract Development And Manufacturing Organization Market (2026 - 2033)

Medical Device Contract Development And Manufacturing Organization Market Summary

The global medical device contract development and manufacturing organization market size was valued at USD 134.7 billion in 2025 and is projected to grow from USD 148.8 billion in 2026 to USD 352.6 billion by 2033, at a CAGR of 13.1% from 2026 to 2033. The market in North America dominated with a revenue share of 48.8% in 2025. The market growth is mainly driven by shifting trends towards outsourcing, the increasing need for specialized expertise, rising demand for advanced products, and the growing shift towards home care and minimally invasive treatments.

The medical device contract development and manufacturing organization (CDMO) market is expanding rapidly as OEMs in large numbers outsource development and manufacturing to address regulatory complexity, high capital costs, and the need for specialized engineering expertise. Besides this, partnering with CDMOs allows OEMs to focus on R&D and commercialization while leveraging scalable production, process validation, and global regulatory support. This trend is particularly strong for minimally invasive, implantable, and connected devices requiring advanced manufacturing and strict compliance. In addition, outsourcing also reduces time-to-market through automation, additive manufacturing, and smart quality systems. In addition, it improves cost efficiency and risk mitigation by utilizing ISO-certified facilities. For instance, in January 2026, Jabil agreed to partner with TxSphere, highlighting the growing reliance on CDMOs for complex drug-device combination products.

In addition, rising demand for advanced medical devices is driving growth in the global medical device CDMO market, as OEMs outsource complex, technology-intensive development and manufacturing. Chronic disease prevalence, aging populations, and adoption of connected diagnostics, AI-enabled systems, and wearable devices are fueling market growth. Besides this, CDMOs provide precision manufacturing, electronics integration, and regulatory expertise, supported by investments in additive manufacturing and automation. In addition, expanding digital health frameworks and streamlined regulatory pathways further accelerate commercialization.

Furthermore, the growing need for highly specialized expertise is a major driver of the medical device contract development and manufacturing organization industry, as rapid innovation and increasing product complexity exceed the in-house capabilities of many manufacturers. Additionally, modern medical devices combine advanced materials, embedded software, miniaturized components, and stringent regulatory requirements, requiring multidisciplinary expertise. In addition, many small and mid-sized OEMs lack the resources to efficiently design, validate, and scale such complex products. Thus, by partnering with CDMOs offering specialized capabilities in design optimization, prototyping, advanced manufacturing, and regulatory compliance, companies can accelerate time-to-market and reduce development risks.

Moreover, the shift toward home care solutions and minimally invasive treatments is accelerating growth in the medical device CDMO industry. Healthcare systems are prioritizing cost reduction, patient comfort, and faster recovery, driving demand for wearable monitors, point-of-care diagnostics, and minimally invasive surgical tools. These devices require advanced materials, embedded software, precision engineering, and strict regulatory compliance capabilities, often outsourced to specialized CDMOs. In addition, home-use products require rigorous usability testing and safety validation. Many OEMs, particularly startups, rely on CDMOs for comprehensive support, from design and prototyping to large-scale manufacturing, sterilization, packaging, and regulatory navigation, strengthening CDMOs’ strategic role.

Opportunity Analysis

The medical device contract development and manufacturing organization market offers significant growth opportunities driven by rising device complexity, increasing outsourcing, and the global shift toward patient-centric care. As OEMs focus on innovation and commercialization, they are in large numbers relying on CDMOs for specialized engineering, regulatory expertise, and scalable manufacturing solutions. In addition, growing demand for minimally invasive devices, wearable technologies, diagnostics, and smart connected systems creates opportunities for CDMOs with advanced capabilities in microfabrication, electronics integration, and additive manufacturing.

Some of the emerging markets expand opportunities as healthcare infrastructure improves and demand for affordable, high-quality devices rises. In addition, strict regulatory standards and quality requirements encourage OEMs to partner with experienced CDMOs that offer compliance expertise and global supply chain resilience. Furthermore, strategic investments in automation, digital manufacturing, and sustainable production practices position CDMOs to capture long-term contracts. As innovation accelerates and product lifecycles shorten, CDMOs are becoming essential partners in driving speed, efficiency, and competitive advantage across the medical device industry.

Impact of U.S. Tariffs on Medical Device Contract Development and Manufacturing Organization Market

The imposition of U.S. tariffs on medical devices and related components has significantly impacted the global medical device CDMO industry. In addition, rising tariffs on imported raw materials, precision parts, and electronic components have increased production costs, further compelling CDMOs to reassess their sourcing models and restructure supply chain strategies and sourcing models. The tariffs have particularly impacted CDMOs reliant on cross-border trade, as cost volatility and margin pressures have intensified market competition across the globe. Thus, many medtech companies have diversified supplier bases, relocated production capabilities, or expanded nearshoring strategies to mitigate risk. At the same time, long-term operations and short-term disruptions have been observed in pricing, lead times, and inventory planning. Moreover, CDMOs with established manufacturing presence and regulatory expertise in the U.S. have gained a competitive advantage. As global medtech companies seek tariff-resilient solutions, CDMOs with flexible supply chains and localized manufacturing capabilities are increasingly well-positioned in the market.

Technological Advancements

Technological advancements are enhancing the market efficiency, innovation & competitiveness with additive manufacturing, especially 3D printing, which supports speeding up the prototyping process, facilitating personalized device solutions. In addition, digital manufacturing and automation play vital roles by optimizing scalability, consistency, and cost efficiency. Further advancements in biomaterials and composites have created safer, more durable, and minimally invasive medical devices, thereby driving rising demand for next-generation implants and wearable technology. Moreover, the rising IoT-enabled smart manufacturing is anticipated to improve the processes through monitoring, predictive maintenance & adherence to regulatory standards, thus enhancing quality and reliability. Further, with these innovations, data-driven process optimization and advanced analytics streamline workflows, reduce waste, and drive innovation across global operations. Thus, these technological advancements in the medtech field are expected to drive the market over the estimated period.

Pricing Model Analysis

The pricing models utilized in the medical device CDMO market are adopted to balance flexibility, transparency, and long-term value for clients & service providers. In the milestone-based pricing model, pricing is tied to deliverables such as design completion, regulatory approval, or production scale-up. This model ensures accountability while managing financial risks in projects. On the other hand, value-based pricing aligns fees with innovation, speed-to-market, and the clinical & commercial impact of the product. This model encourages partnerships among medical device companies and CDMOs, further offering strategic value in the model. Moreover, the fixed-fee model offers cost predictability, making it suitable for manufacturing & regulatory processes. Further, the subscription models provide access to expertise through regular payments, which are used for requirements such as quality management or supply chain oversight. Thus, these pricing models offer an innovative strategy that caters to a wide range of client needs while promoting sustainable growth for CDMOs.

Market Characteristics

The medical device contract development and manufacturing organization market is at a high-growth stage, with an accelerating pace. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.

The medical device contract development and manufacturing organization industry’s growth is accelerated by adopting automation, additive manufacturing, and IoT-enabled systems. In addition, partnerships with device developers further drive the development of personalized solutions, wearables, and drug-device combinations. Besides, continuous investment in R&D, rapid prototyping, and advanced materials integration support the CDMOs to remain at the forefront of medtech innovation, delivering faster, safer & more effective products to the global market.

The evolving regulatory frameworks, such as the EU MDR and U.S. FDA requirements, have significantly influenced CDMO operations in the medical device industry. In addition, strict compliance ideally requires robust quality management systems, traceability, and documented processes, which are expected to support the market. While these standards exist, the operational costs further create new opportunities for CDMOs with strong regulatory expertise. In addition, compliance has become a challenge and a differentiator, positioning capable partners as highly valued in medtech supply chains.

Mergers and acquisitions within the medical device CDMO market have increased the companies' pursuit of scale, technological capabilities, and geographic reach. In addition, the consolidation is driven by diversifying service portfolios and meeting rising client expectations. Acquiring niche technology providers and regional players has enabled CDMOs to expand competencies, strengthen market positioning, and compete more effectively in a highly fragmented global landscape. For instance, in January 2026, Arterex acquired Ireland-based medical injection-molding company Synecco Ltd., expanding its European presence and strengthening its capabilities in cardiovascular medical device manufacturing.

Service expansion has emerged as a core growth strategy for medical device CDMOs. The companies are moving beyond manufacturing to offer integrated solutions, including design, prototyping, testing, regulatory consulting, and supply chain management. This end-to-end approach enhances client value by streamlining development timelines, reducing outsourcing complexity, strengthening partnerships, and expanding revenue streams, which are expected to drive the market.

It remains a significant factor among the market players to establish their footprints in high-demand markets such as North America, Europe, and Asia Pacific. Besides, emerging economies offer cost advantages and growing healthcare demand, particularly in Asia. Strategic local presence enables CDMOs to navigate regulatory requirements, serve clients more effectively, strengthen global supply chains, and capture new growth opportunities.

Product Insights

The therapeutics segment held the largest market share of 52.22% in 2025, due to the complexity, high value, and clinical importance of devices such as implants, infusion pumps, neurostimulators, and cardiac systems. In addition, the rising prevalence of chronic diseases is increasing demand for advanced therapeutic solutions. These devices require specialized engineering, strict regulatory compliance, sterilization, and rigorous quality assurance, prompting OEMs to outsource to experienced CDMOs. CDMOs provide comprehensive support from design and prototyping to manufacturing scale-up and post-market surveillance. Besides this, technological advancements, including miniaturization and smart drug-device combinations, further drive outsourcing, reinforcing the segment’s leading market share.

The drug-device combination products segment is experiencing the fastest growth in the medical device contract development and manufacturing organization industry, driven by the increasing demand for integrated therapeutic solutions that combine pharmaceuticals with specialized delivery devices. These products include injectable pens, inhalers, prefilled syringes, transdermal patches, and implantable combination systems, which enable precise, controlled, and patient-friendly drug administration. In addition, growth in this segment is fueled by the rising prevalence of chronic diseases such as diabetes, respiratory disorders, and cardiovascular conditions, where effective drug delivery is critical for patient outcomes.

Service Insights

The contract manufacturing segment held the largest revenue share in 2025 and is expected to grow at the fastest CAGR during the forecast period. This segment comprises accessories manufacturing, assembly manufacturing, component manufacturing, and device manufacturing. OEMs seek scalable, cost-efficient, and compliant production solutions. In addition, the growing demand for complex devices, including implants, diagnostics, and minimally invasive systems, requires advanced manufacturing, cleanroom operations, sterilization, and strict regulatory compliance. In addition, outsourcing reduces capital investment, mitigates operational risk, and accelerates time-to-market. Furthermore, CDMOs offer flexible capacity, small-batch production, and compliance with ISO 13485, FDA, and EU MDR standards. Thus, the adoption of automation and digital manufacturing improves efficiency and traceability.

The contract development segment is the second-fastest-growing in the market and includes product design and development services, testing & validation, quality management, and other services. Increasing demand for innovative devices, including implants, diagnostics, combination products, minimally invasive systems, and digital health solutions, drives the need for end-to-end development support. Furthermore, CDMOs offer capabilities such as rapid prototyping, additive manufacturing, bench testing, risk management, and design validation aligned with ISO 13485, FDA, and EU MDR standards. As device complexity, software integration, and global regulatory requirements rise, OEMs rely on CDMOs to accelerate innovation, reduce risk, and streamline approvals across multiple markets.

Class Insights

The class II segment captured a considerable share of the medical device contract development and manufacturing organization market in 2025, driven by their moderate to high complexity, greater patient risk, and stringent regulatory requirements. The devices, such as infusion pumps, imaging components, electrosurgical tools, and monitoring systems, require precision engineering, robust quality control, and compliance across global standards, encouraging OEMs to outsource to specialized CDMOs. In addition, growing demand for minimally invasive procedures, homecare technologies, and advanced diagnostics further supports this trend.

On the other hand, the class I segment is expected to grow at the second-fastest CAGR over the forecast period. Class I medical devices are essentially noninvasive, accounting for around 47% of all devices. Due to their low risk profile, nearly 95% are exempt from regulatory procedures, making them the easiest and fastest to access in the market. These devices rarely play a critical role in life-sustaining care. While most Class I devices are exempt from the FDA’s Premarket Notification (510(k)) and Premarket Approval (PMA) requirements, they remain subject to FDA general controls. These include provisions on misbranding, device registration, recordkeeping, and adherence to good manufacturing practices. Manufacturers must also implement quality management systems and comply with industry standards to ensure consistent product quality and patient safety. Such factors are expected to drive the market over the estimated time period.

Application Insights

The cardiovascular devices segment captured the considerable share of the medical device contract development and manufacturing organization industry in 2025. The cardiovascular devices application segment is experiencing growth, driven by the rising global prevalence of cardiovascular diseases and the increasing adoption of advanced, minimally invasive treatment solutions. Devices such as stents, catheters, heart valves, pacemakers, defibrillators, and structural heart repair systems require high levels of precision, biocompatible materials, and strict regulatory compliance, making outsourced development and manufacturing an attractive option for device manufacturers. OEMs are partnering with CDMOs to leverage specialized capabilities in design engineering, prototyping, precision manufacturing, sterilization, validation, and quality management, which are critical for cardiovascular applications. The shift toward transcatheter and minimally invasive cardiovascular procedures has further accelerated demand for complex, next-generation devices that require advanced manufacturing processes and rigorous testing.

The surgical instruments segment is expected to be the fastest-growing segment over the forecast period, as healthcare systems worldwide continue to prioritize advanced surgical care and procedural efficiencies. This segment includes a wide range of products, including scalpels, forceps, clamps, retractors, endoscopic instruments, laparoscopic tools, electrosurgical devices, and other precision surgical tools used across various clinical specialties. Growth is driven by the increasing volume of minimally invasive and robotic-assisted surgeries, which demand high-precision, customized instruments that meet strict quality and performance standards.

End Use Insights

The original equipment manufacturers (OEMs) segment accounted for the largest share of the medical CDMO industry in 2025 and is expected to grow at the fastest CAGR during the forecast period. OEMs are increasingly partner with medical device CDMOs to enhance product development and manufacturing. These CDMOs provide services such as design optimization, component sourcing, regulatory compliance, and large-scale production to optimize the medical device production. In addition, these collaboration allows OEMs to reduce costs, accelerate timelines, and focus on innovation & commercialization. With expertise in advanced manufacturing technologies and global supply chain management, CDMOs ensure high-quality output and compliance with international standards, further contributing to market growth. Moreover, CDMOs enable OEMs to expand product portfolios, penetrate new markets, and maintain competitiveness in the evolving medical device landscape. Such factors are expected to drive the market growth over the forecast period.

The pharmaceutical & biopharmaceutical companies segment is expected to grow at the second-highest CAGR during the forecast period. Pharmaceutical and biopharmaceutical companies increasingly rely on medical device CDMOs to develop drug-delivery systems, combination products, and diagnostics. Besides, the CDMOs offer end-to-end services from early-stage design to regulatory approvals and commercial-scale production, contributing to market growth. Moreover, material selection, device engineering, and compliance ensure effective integration of drug & device components, further supporting device innovation. Furthermore, outsourcing offers capabilities, cost efficiencies, and faster product launches to bring innovative therapies and delivery solutions to the global market. Such factors are expected to drive the market.

Regional Insights

North America Medical Device Contract Development And Manufacturing Organization Market

North America dominated the global medical device CDMO market in 2025, with a 48.78% revenue share. A strong regulatory framework, advanced R&D infrastructure & rising demand for innovative healthcare technologies drive the market growth. Most medtech companies are increasingly outsourcing design, development, and manufacturing to optimize costs, accelerate time-to-market, and access specialized expertise. Besides, the region benefits from established medtech players, favorable reimbursement policies, and rising adoption of minimally invasive and digital health solutions. Moreover, for emerging medical devices, the high cost of R&D is a significant challenge, which has encouraged various medical device companies in North America to outsource functions to third-party vendors with high levels of expertise in the domain. Moreover, medical device companies are increasingly collaborating with CDMOs as these service providers offer flexible capacity, specialized technologies, and faster development timelines. Such factors are expected to drive the market growth.

U.S.  Medical Device Contract Development And Manufacturing Organization Market Trends

The medical device contract development and manufacturing organization industry in the U.S. led North America with the largest revenue share in 2025, owing to rising demand for advanced medical technologies, cost optimization needs, and stringent regulatory requirements. Besides, OEMs in the region are increasingly outsourcing medical device design, prototyping, component production, and assembly to CDMOs to enhance efficiency & reduce time-to-market. Moreover, strong R&D infrastructure, skilled workforce, and robust regulatory frameworks have contributed to market growth. In addition, rising adoption of minimally invasive devices & complex therapeutic solutions is expected to drive the innovation and market competitiveness in the U.S.

The Canada medical device contract development and manufacturing organization market is expected to grow at a significant CAGR during the forecast period. A robust healthcare ecosystem, favorable government initiatives, and an increasing demand for cost-effective device production drive the market growth. Besides, the CDMOs in the region offer a range of expertise in medical device design, prototyping, regulatory compliance, and manufacturing, which helps OEMs streamline their operations. Moreover, the country focuses on innovation and advanced manufacturing technologies to enhance the supply chain, further strengthening the market. In addition, collaborations with established companies and investments in technology advancements are expected to establish the country as a competitive hub for medical device outsourcing. Such factors are expected to drive the market over the estimated time period.

Europe Medical Device Contract Development And Manufacturing Organization Market Trends

Europe's medical device CDMO market is evolving rapidly, supported by a strong medical device industry base, and the presence of EU5 countries: the UK, Germany, France, Italy, and Spain. These countries benefit the market due to the presence of advanced technologies and well-established infrastructure. Moreover, companies looking to enter the European market require extensive knowledge of product design complexity, further driving demand for medical device CDMO services.  In addition, small to mid-sized medical device companies are increasingly seeking CDMO services to ensure the performance and safety of products in the region. Moreover, the market is expected to witness new growth opportunities driven by stringent regulatory policies, superior manufacturing capabilities, and increased investments by multinational corporations.

The medical device contract development and manufacturing organization market in Germany held the largest revenue share in 2025. The country’s medical technology market consists of 95% of small and medium-sized companies or sub-groups of larger companies. Germany produces high-quality medical equipment, with a focus on diagnostic imaging, optical technologies, dental products, and surgical instruments. Moreover, growth is driven by strong medical device manufacturing hubs, advanced R&D activities, shorter product development cycles, improved organizational effectiveness, and greater access to higher technology through outsourced consulting services. In addition, the German CDMOs are emphasizing precision, regulations, and investment in state-of-the-art technologies, further supporting the medical device industry.

The UK medical device contract development and manufacturing organization market is expected to grow significantly over the forecast period. Several key factors driving market growth are the presence of various multinational medical device companies, significant R&D spending, well-established healthcare infrastructure, healthcare research, high healthcare spending, and an increasing demand for medical device CDMO services that facilitate the development of new products.

Asia Pacific Medical Device Contract Development And Manufacturing Organization Market Trends

The Asia Pacific medical CDMO industry is expected to grow at the fastest CAGR over the forecast period. The market is experiencing robust expansion, driven by cost advantages, a skilled technical workforce, and large-scale manufacturing hubs. Besides, the presence of countries such as China, India, and Japan is emerging as a key country for medical device CDMO services due to favorable government policies, infrastructure development, and rising healthcare investments. Moreover, the evolving innovation in medical devices and the presence of established healthcare infrastructure, supported by government initiatives, are expected to drive the market over the estimated time period. Furthermore, rising demand for comprehensive services, including design, engineering, component manufacturing, and regulatory support, is anticipated to accelerate commercialization in the regional market.

The medical device contract development and manufacturing organization market in China is witnessing new growth opportunities due to government initiatives, a vast patient pool, and the presence of a well-established pharmaceutical and biotechnology ecosystem. Besides, the country has become a major destination for medical device CDMO services due to rapid technological advancements, rising demand for new, cost-effective medical devices, and high healthcare expenditures. In addition, strategic partnerships with multinational companies and R&D capabilities have further strengthened the market presence, and large-scale manufacturing facilities enable global supply. Such factors are expected to drive the market.

The Japan medical device contract development and manufacturing organization market is expected to grow, driven by the expanding medical devices industry, rapid technological advancements, increasing demand for outsourcing services, and rising healthcare expenditures. In addition, the market dynamics in Japan have led many medical device manufacturers to prefer CDMO services to develop new high-quality products for various therapeutics, which is anticipated to further contribute to market growth. Moreover, the presence of a stringent regulatory framework and standards for medical device manufacturing is fueling the market growth.

The medical device contract development and manufacturing organization market in India is experiencing rapid expansion, driven by cost advantages and the growing range of medical devices for various disease diagnoses. Additionally, many global medical device companies outsource manufacturing to India. It has become a preferred destination for medical device companies to outsource CDMO services due to lower labor costs, improved healthcare infrastructure, and a substantial number of technical experts. Such aforementioned factors are expected to drive the market.

Latin America Medical Device Contract Development and Manufacturing Organization Market Trends

The medical device contract development and manufacturing organization industry in Latin America is expected to grow significantly over the estimated study period. In Latin America, the market is developing steadily, supported by increasing healthcare investments, expanding patient populations, and growing demand for affordable medical technologies. Besides, Brazil and Argentina are leading countries in the region with improving regulatory frameworks and skilled manufacturing capabilities. In addition, regional CDMOs provide a range of services from designing, prototype to large-scale production, further enabling medical device companies to optimize their cost and expand the market reach. Thus, the market is expected to witness untapped opportunities for medical devices seeking to expand regional presence, further supporting the market growth.

The medical device contract development and manufacturing organization market in Brazil is rising healthcare expenditure, a large patient base, and government initiatives promoting local production. Besides, the CDMOs in the country are strengthening their capabilities in design, prototyping, and manufacturing to meet the growing demand for cost-effective medical devices. Moreover, growing partnerships with OEMs are expected to drive the market further, making it an emerging strategic hub for medical device outsourcing in Latin America.

Middle East and Africa Medical Device Contract Development And Manufacturing Organization Market Trends

The Middle East & Africa (MEA) medical device CDMO market is witnessing significant growth, driven by expanding healthcare infrastructure, rising prevalence of chronic and lifestyle diseases, and increasing government focus on domestic healthcare capabilities. Strategic national initiatives, such as Saudi Arabia’s Vision 2030 and the UAE’s Vision 2031, emphasize healthcare localization, advanced manufacturing, and medical technology self-sufficiency, creating favorable conditions for both domestic and international medical device CDMOs. These initiatives provide incentives for infrastructure investment, technology transfer, and workforce development, encouraging global OEMs to collaborate with local partners for outsourced R&D, contract manufacturing, clinical evaluation, and regulatory services.

The South Africa medical device contract development and manufacturing organization market is expanding due to the development of healthcare infrastructure, rising demand for advanced diagnostic and therapeutic devices, and the increasing prevalence of chronic and lifestyle diseases. The availability of a skilled workforce, coupled with technical expertise in precision manufacturing, assembly, and validation, enables local CDMOs to provide specialized services to global and domestic OEMs. Cost-effective manufacturing, supported by government incentives for local production and import substitution, further attracts outsourcing partnerships. Strategic investments are also fueling innovation and capacity expansion, for instance, in December 2025, the SAB Foundation invested R28 million in Cape Town-based start-up LIQID Medical to advance the development of innovative ocular implants for glaucoma, highlighting the growing support for high-value, specialized device development.

The UAE medical device contract development and manufacturing organization market is experiencing growth, fueled by strategic investments in healthcare infrastructure, advanced manufacturing, and digital technologies. Some of the programs, such as UAE Vision 2031 and initiatives like the Emirati Genome Program, are accelerating precision medicine, genomics, and research on rare diseases, positioning the UAE as a regional hub for high-value medical device development and production. In addition, advanced digital platforms, AI-driven manufacturing analytics, and integrated quality management systems enable more efficient, precise, and compliant contract manufacturing, boosting demand for outsourced device production, assembly, testing, and lifecycle management. For instance, UAE-based CDMOs are leveraging these capabilities to deliver globally competitive manufacturing solutions, attracting both local and international OEMs. 

Key Medical Device Contract Development And Manufacturing Organization Company Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in January 2026, Jabil acquired Hanley Energy Group for about USD 725 million (plus up to USD 58 million in contingent), strengthening its data center power management and energy optimization capabilities to support growing AI-driven infrastructure demand. 

Recent Developments

• In January 2026, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to integrate AI-powered solutions into scientific instruments and laboratory workflows, aiming to improve automation, accuracy, and speed of laboratory operations and accelerate scientific discovery.

• In November 2025, Sanmina announced the expansion of its Fermoy, Ireland, medical manufacturing facility, which is expected to create up to 150 skilled jobs, while adding advanced automation lines, an ISO 8 cleanroom, and high-volume production capabilities for wearable medical devices, strengthening its position in finished medical device manufacturing in Europe.

• In March 2025, Flex opened a new healthcare-focused Product Introduction (NPI) Center near Boston, Massachusetts, providing end-to-end product development support from prototyping and preclinical builds to design verification and production transfer, enhancing speed-to-market and scalable manufacturing for medical device and healthcare technology customers.

Medical Device Contract Development And Manufacturing Organization Market Report Scope

Global Medical Device Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global medical device contract development and manufacturing organization market report based on product, service, class, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Diagnostics

  • Therapeutics

  • Drug-Device Combination Products

• Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Contract Development

    • Product Design and Development Services

    • Testing & Validation

    • Quality Management

    • Others

  • Contract Manufacturing

    • Accessories Manufacturing

    • Assembly Manufacturing

    • Component Manufacturing

    • Device Manufacturing

  • Packaging

  • Regulatory Affairs

  • Others

• Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Class I

  • Class II

  • Class III

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Cardiovascular Devices

  • Orthopedic Devices

  • Ophthalmic Devices

  • Diagnostic Devices

  • Respiratory Devices

  • Surgical Instruments

  • Dental

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Original Equipment Manufacturers (OEMs)

  • Pharmaceutical & Biopharmaceutical Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • UAE

    • Saudi Arabia

    • Kuwait

    • Qatar

    • Oman